


## Description

Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ) are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-GPC3 (glypican 3) (clone GC33) linked to a 2<sup>nd</sup> generation CAR (Chimeric Antigen Receptor), containing an IgG1 short hinge and CD28 transmembrane domain, 4-1BB and CD3ζ signaling domains (Figure 1).

These lentiviruses have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

A.



B.




Figure 1: Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ) construct diagrams.

(A) Schematic of the lenti-vector used to generate the anti-GPC3 CAR lentivirus. (B) Construct diagram showing components of the anti-GPC3 CAR.

## Background

GPC3, also known as Glypican-3 and OCI5, belongs to the glypican family and is highly expressed in the lungs, liver and kidneys. Its function is tissue dependent and can either promote or suppress tumorigenesis. Being a heparin sulfate proteoglycan, it is overexpressed in neoplasms including malignant melanoma, hepatocellular carcinoma, and testicular yolk sac tumors and plays a significant role in cell growth and differentiation. Due to its highly restricted expression in normal tissues and high prevalence in many solid tumors, GPC3 has become an attractive target for chimeric antigen receptor (CAR) T cell therapy.

### Application

- Positive control for anti-GPC3 CAR evaluation in T cells.
- Transduction optimization experiments.
- Generate anti-GPC3 CAR-T cells (for research use only, not for therapeutic purposes).

### Formulation

The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM. Virus particles can be packaged in custom formulations upon special request, for an additional fee.

### Size and Titer

50 µl at a titer  $\geq 3 \times 10^8$  TU/ml. The titer may vary with each lot; the exact value is provided with each shipment.

### Storage Conditions



Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the virus at -80°C for up to 12 months from the date of receipt. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

### Biosafety



The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (*gag*, *pol*, *rev*) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

### Materials Required but Not Supplied



These materials are not supplied but are necessary for cell culture and for the cellular assays described below. BPS Bioscience's reagents are validated and optimized for use with this product and are highly recommended for best results.

| Name   | Ordering Information                   |
|--|--|
| PBMC, Frozen   | <a href="#">BPS Bioscience #79059</a>  |
| TCellM™  | <a href="#">BPS Bioscience #78753</a>  |
| Human Interleukin-2 Recombinant                          | <a href="#">BPS Bioscience #90184</a>  |
| EasySep™ Human CD4+ T Cell Isolation Kit                 | STEMCELL™ TECHNOLOGIES #17952          |
| EasySep™ Human CD8+ T Cell Isolation Kit                 | STEMCELL™ TECHNOLOGIES #17953          |
| Human CD3/CD28/CD2 T Cell Activator                      | STEMCELL™ TECHNOLOGIES #10970          |
| Lenti-Fuse™ Polybrene Viral Transduction Enhancer        | <a href="#">BPS Bioscience #78939</a>  |
| Firefly Luciferase A549 Cell Line                        | BPS Bioscience #82495                  |
| Firefly Luciferase HepG2                                 | BPS Bioscience #82490                  |
| Thaw Medium 1  | <a href="#">BPS Bioscience #60187</a>  |
| Thaw Medium 6  | <a href="#">BPS Bioscience #60183</a>  |
| GPC3, Avi-His-Tagged, Biotin-Labeled Recombinant         | <a href="#">BPS Bioscience #100072</a> |
| PE anti-Biotin Antibody                                  | BioLegend # 409003                     |
| ONE-Step™ Luciferase Assay System                        | <a href="#">BPS Bioscience #60690</a>  |
| Clear-bottom, white 96-well tissue culture-treated plate | Corning #3610                          |

## Media Formulations

**T Cell Medium:** TCellM™ (BPS Bioscience #78753) supplemented with 10 ng/ml Interleukin-2 (BPS Bioscience #90184).

## Assay Protocol

### A. Primary T Cell Transduction Protocol

The following protocol was used to transduce CD4<sup>+</sup> and CD8<sup>+</sup> primary T cells with Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3Z). The transduction conditions (e.g. MOI, concentration of polybrene, time of assay development) should be optimized according to the cell type and the assay requirements.

#### Day 0:

1. Isolate CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells from previously frozen human PBMC by negative selection, according to manufacturer's instruction.
2. Mix the isolated CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells at a 1:1 ratio.
3. Culture the cells using the recommended T Cell Medium at 1 x 10<sup>6</sup> cells/ml density at 37°C with 5% CO<sub>2</sub> overnight.

#### Day 1:

1. Add T cell activation reagents to the cells according to manufacturer's instruction.

2. Incubate cells at 37°C with 5% CO<sub>2</sub> for 24 - 48 hours.

**Day 2:**

1. Centrifuge T cells (300 x g for 5 minutes) and resuspend in fresh T Cell Medium at 0.1 - 1 x 10<sup>6</sup> cells/ml.
2. Add Lenti-Fuse™ Polybrene Viral Transduction Enhancer (5 µg/ml) to the cells.
3. Thaw Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ) on ice.

*Note: Lentiviruses are very sensitive to freeze/thaw cycles. Following the first thaw, prepare small aliquots of virus to limit cycles of freeze/thaw.*

4. Perform spinoculation as follows:
  - 1) Distribute 100 µl of T cells (~10,000-100,000) into each 1.5 ml Eppendorf tube.
  - 2) Add viruses to the cells. Titrate the MOI, starting at an MOI of 10.
  - 3) Incubate the lentivirus/cells mix in the hood at Room Temperature (RT) for 10 minutes.
  - 4) Spin the cells/virus mix gently at 800 x g for 2 hours at 32°C.
  - 5) If using 10,000 cells, add 900 µl of fresh T Cell Medium into each well of a 24-well plate followed by the cells/virus mix.  
If using 100,000 cells, add 3 ml of fresh T Cell Medium into each well of a 6-well plate, followed by the cells/virus.

*Note: It is not necessary to remove the virus.*


5. Incubate the cells at 37°C with 5% CO<sub>2</sub> for ~48-72 hours.

**Day 7-14:**

1. The expression of the anti-GPC3 CAR can be estimated by flow cytometry.
2. Expand cells in T Cell Medium, if desired. These can be frozen in Cryostor® CS10 (BioLife Solutions).

*Note: Once the transduced cells have proliferated sufficiently to reach the desired cell number required for your experiments, it is recommended the cells are used, to minimize cellular exhaustion. In the experience of scientists at BPS Bioscience, the T cells can expand >1000 fold by 11 days post-transduction, when using TCellM™ supplied with IL-2.*

## Validation Data



*Figure 2. Expression of anti-GPC3 CAR in T cells transduced with Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ).*

Approximately 30,000 CD4<sup>+</sup> and CD8<sup>+</sup> activated T cells were transduced with 600,000 TU (MOI of 20) of Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ) in the presence of 5 μg/ml of Lenti-Fuse™ Polybrene Viral Transduction Enhancer by spinoculation. Anti-GPC3 CAR expression was analyzed by flow cytometry 5 days post-transduction (green). Untransduced T cells were used as control (blue). GPC3, Avi-His-Tagged, Biotin-Labeled Recombinant (BPS Bioscience #100072) and PE anti-Biotin Antibody (BioLegend # 409003) were used for anti-GPC3 CAR detection. Y axis represents the % cell number. The X axis indicates fluorophore intensity.

## Functional Validation

### Cytotoxicity assay of Anti-GPC3 CAR-T Cells using Firefly Luciferase A549 Cell Line and Firefly Luciferase HepG2 Cell Line as the target cells

- The following assay was designed for a 96-well format. To perform the assay in different tissue culture formats, the cell number and reagent volume should be scaled appropriately.
- All conditions should be performed in triplicate.
- The assay should include “Background Control”, “No T Cell Control” and “Test” conditions.
- The following experiments are an example of co-culture assays where Firefly Luciferase A549 Cell Line(#82495) (low GPC3 expression level) and Firefly Luciferase HepG2 Cell Line (#82490) (high GPC3 expression level) are used to evaluate the cytotoxicity of Anti-GPC3 CAR-T Cells (#82492).
- We recommend the use of Untransduced T Cells (Negative Control for CAR-T cells) (#78170) as control.

**T Cell Medium:** TCellM™ (#78753) supplemented with 10 ng/ml of Interleukin-2 (#90184).

### Day 0

1. Thaw frozen Anti-GPC3 CAR-T cells and control cells in T Cell Medium.
2. Incubate at 37°C for 24 hours.

**Day 1**

1. Seed Firefly Luciferase A549 cells and Firefly Luciferase HepG2 cells in 50 µl of Thaw Medium 6 and Thaw Medium 1, respectively, at 500 cells/well in a 96-well white, clear bottom tissue culture plate. Leave a few empty wells as “Background Control”.
2. Centrifuge T cells gently and resuspend in fresh T Cell Medium at the appropriate cell density to reach the desired effector:target (E:T) cell ratio (50 µl/ well).
3. Carefully pipet 50 µl of T cells into each well at the desired effector:target (E:T) cell ratio to the “Test” wells.
4. Add 50 µl of fresh T Cell Medium to the “No T Cell Control” wells.
5. Add 100 µl of fresh T Cell Medium to the “Background Control” wells.
6. Incubate at 37°C for 24 hours.

*Note: No overnight attachment is needed for the adherent target cells. T cells can be added into the wells 1-2 hours after the target cells were seeded.*

**Day 2**

1. Add 50 µl of ONE-Step™ Luciferase assay reagent was added to each well.
2. Incubate at Room Temperature (RT) for ~15 to 30 minutes before measuring luminescence using a luminometer.

Data Analysis: the average background luminescence was subtracted from the luminescence reading of all wells. The luciferase activity of Firefly Luciferase A549 cells and Firefly Luciferase HepG2 cells was set as 100%. The % Luminescence was calculated as background-subtracted luminescence of co-culture wells divided by background-subtracted luminescence of the “No T Cell Control” wells (Firefly Luciferase A549 cells and Firefly Luciferase HepG2 cells only).

$$\% Lum = \frac{Lum\ coculture - background}{Lum\ control - background} * 100$$




Figure 3. Luciferase-based cytotoxicity assay of T cells transduced with Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ) using Firefly Luciferase HepG2 Cell Line and Firefly Luciferase A549 Cell Line as target cells.

Approximately 30,000 CD4<sup>+</sup> and CD8<sup>+</sup> T cells were transduced with 600,000 TU (MOI of 20) of Anti-GPC3 CAR Lentivirus (Clone GC33-CD28TM-41BB-CD3ζ) in the presence of 5 μg/ml of Lenti-Fuse™ Polybrene Viral Transduction Enhancer by spinoculation. The transduced T cells were expanded and frozen on day 12. The thawed T cells (effector) were co-cultured with Firefly Luciferase HepG2 cells or Firefly Luciferase A549 cells as the target cells (target) for 24 hours at indicated E:T ratios. The lysis of the target cells was determined by measuring luciferase activity with ONE-Step™ Luciferase Assay System. The assay was performed in parallel with untransduced T cells as a negative control.

Data shown is representative.

#### License Disclosure

Visit [bpsbioscience.com/license](https://bpsbioscience.com/license) for the label license and other key information about this product.

#### Troubleshooting Guide

Visit [bpsbioscience.com/lentivirus-faq](https://bpsbioscience.com/lentivirus-faq) for detailed troubleshooting instructions. For lot-specific information and all other questions, please visit <https://bpsbioscience.com/contact>.

**Related Products**

| <i>Products</i>   | <i>Catalog #</i> | <i>Size</i> |
|---|------------------|-------------|
| Untransduced T cells (Negative Control for CAR-T Cells)     | 78170            | 1 vial      |
| Anti-GPC3 CAR-T cells                                       | 82492            | 1 vial      |
| Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ)         | 78600            | 50 μl       |
| Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-CD28-CD3ζ) | 78655            | 50 μl       |
| Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ) | 78606            | 50 μl       |
| Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ)   | 78608            | 50 μl       |

*Version 060525*